In a phase I/II trial, human leukocyte antigen-mismatched anti-CD19 CAR-NK cells derived from cord blood were infused into 11 patients with relapsed or refractory CD19-positive cancers; 73% of patients (8/11) had a response and seven patients had a complete remission without development of major toxic effects (Liu et al., 2020). The gene discussed is CD19; the disease is cancer.